secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001193125-23-277184
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal refinances $2.13B term loans extending maturity to 2028; ABL facility upsized to $600M
--------------------------------------------------------------------------------

- Exchanged $2.13B of existing term loans due 2025 for new term loans due 2028; remaining $192M old loans unchanged.
- New term loan interest margin set at 5.50% (SOFR) vs 3.50% on old loans; 5% exchange fee paid to consenting lenders.
- ABL revolving credit facility increased to $600M with maturity June 2, 2027; margins 1.25%-1.50% over SOFR.
- No financial covenants in new term loan agreement; secured by substantially all assets of loan parties.
- Transaction completed on Nov 14, 2023; total new term loans outstanding $2.35B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000119312523277184/0001193125-23-277184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000119312523277184/d78181d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-277184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer